The Asthma market report also offers comprehensive insights into the Asthma market size, share, Asthma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Asthma market size growth forward.
Some of the key highlights from the Asthma Market Insights Report:
-
Several key pharmaceutical companies, including GlaxoSmithKline, Teva Pharmaceuticals, Launch Therapeutics, AB Science, AstraZeneca, Areteia Therapeutics, Knopp Biosciences, Palobiofarma SL, Pivotal S.L., Sterna Biologicals, Sanofi, Connect Biopharma, and others, are developing novel products to improve the Asthma treatment outlook.
-
According to DelveInsight’s estimates, there were approximately 55 million diagnosed prevalent cases of asthma in the 7MM in 2023. The United States accounted for 47% of these cases, while the EU4 and the UK represented nearly 45%, and Japan accounted for 8%.
-
The asthma market is projected to grow steadily, with a compound annual growth rate (CAGR) of 1.6% forecasted from 2024 to 2034. This growth will be driven by the introduction of innovative therapies such as Depemokimab (GSK3511294), Masitinib, and BREZTRI AEROSPHERE (PT010), along with an increasing prevalence of asthma due to urbanization and environmental factors. Advances in personalized medicine and smart inhalers also contribute to market expansion.
-
In 2023, the asthma market in the 7MM was valued at approximately USD 20.6 billion. Despite the availability of six FDA-approved biologics—CINQAIR (reslizumab), FASENRA (benralizumab), NUCALA (mepolizumab), DUPIXENT (dupilumab), TEZSPIRE (tezepelumab-ekko), and XOLAIR (omalizumab)—current treatments often provide limited symptom relief and can have significant side effects, highlighting the need for more targeted therapies to improve outcomes and reduce recurrence.
-
Key players like AstraZeneca, GlaxoSmithKline, and AB Science are driving innovation through the development of new assets, shaping the asthma treatment landscape and creating opportunities for market growth.
-
On October 7, 2024, AstraZeneca reported positive outcomes from the Phase IIIb BATURA trial, showing that Airsupra (a combination of albuterol and budesonide) significantly lowered the risk of severe exacerbations in asthma patients. The trial focused on individuals with intermittent or mild persistent asthma and demonstrated that using Airsupra as an as-needed rescue medication was more effective than albuterol alone, offering a clinically meaningful reduction in exacerbation risk.
-
In September 2024, GSK presented positive Phase III trial results from SWIFT-1 and SWIFT-2 for depemokimab in treating severe asthma at the European Respiratory Society International Conference.
-
As per DelveInsight analysis, the Asthma market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Asthma Market Landscape
Asthma Overview
Asthma is a chronic inflammatory condition of the airways characterized by episodic and reversible airway obstruction. It involves immune responses, airway remodeling, and heightened sensitivity to triggers, leading to symptoms like wheezing, coughing, chest tightness, and shortness of breath. Symptoms often worsen at night or in response to triggers such as allergens (e.g., pollen, dust, animal dander, mold), irritants (e.g., pollutants, perfumes), and environmental factors like exercise or cold air.
Asthma is classified by severity (intermittent to severe persistent), type of triggers (allergic, non-allergic, exercise-induced), and type of airway inflammation (eosinophilic, non-eosinophilic). These classifications guide personalized treatment and management strategies. Diagnosis typically involves a medical history, physical examination, and lung function tests, such as the FeNO test, which detects lung inflammation, and spirometry, which measures lung capacity and airflow.
Do you know the treatment paradigms for different countries? Download our Asthma Market Sample Report
Asthma Epidemiology Insights
-
According to DelveInsight’s analysis, the United States recorded approximately 4.8 million pediatric and 21.2 million adult asthma cases in 2023, with these numbers projected to increase by 2034.
-
In the EU4 and the UK, the highest number of asthma cases in 2023 was reported in the UK (8.4 million), followed by Germany (4.9 million) and France (4.7 million), with changes expected during the forecast period (2024–2034).
-
Among asthma cases in the EU4 and the UK, intermittent cases were the most prevalent in 2023. For example, Germany accounted for approximately 1.7 million intermittent cases, followed by moderate, mild, and severe cases in descending order.
Asthma Epidemiology Segmentation
DelveInsight’s Asthma market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Asthma historical patient pools and forecasted Asthma patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Asthma Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
-
Asthma Prevalence
-
Age-Specific Asthma Prevalence
-
Gender-Specific Asthma Prevalence
-
Diagnosed and Treatable Cases of Asthma
Visit for more @ Asthma Epidemiological Insights
Asthma Market Insights:
-
In 2023, the asthma market in Japan was valued at around USD 1,047 million, with expectations for growth throughout the forecast period (2024-2034).
-
It is estimated that TEZSPIRE (tezepelumab-ekko) will generate approximately USD 1,975 million in the 7MM by 2034.
Asthma Market Outlook
Asthma is a prevalent and serious global health issue, characterized by respiratory symptoms like shortness of breath, wheezing, chest tightness, and coughing, along with airflow limitation caused by bronchoconstriction, airway thickening, and increased mucus production.
The main treatment goal is to reduce symptoms and prevent complications such as fixed airflow limitation, exacerbations, and side effects from medications. Asthma management follows guidelines that focus on assessing the severity of the condition and choosing the appropriate treatments to control symptoms and reduce exacerbation risks.
Asthma treatment is typically stepwise, beginning with quick-relief medications and progressing to long-term control options. Quick-relief therapies include inhaled short-acting beta2-agonists (SABAs) and corticosteroids, though they are no longer recommended alone due to the risk of severe exacerbations. A recent advancement is AIRSUPRA, a 2023-approved combination of albuterol (SABA) and budesonide (ICS), which offers better safety and efficacy.
Long-term management includes inhaled corticosteroids (ICS), biologics like TEZSPIRE (tezepelumab) and FASENRA (benralizumab), and triple therapies combining ICS, LABA, and LAMA for improved disease control. Despite available treatments, unmet needs remain due to the lack of curative options and varied responses across asthma phenotypes. Emerging biologics targeting specific inflammatory pathways show promise for improving outcomes, particularly in severe asthma cases.
In 2023, the asthma market in the seven major markets was valued at approximately USD 20.6 billion.
Asthma Marketed Drugs
-
AIRSUPRA (albuterol and budesonide): AstraZeneca/Avillion
-
TEZSPIRE (tezepelumab): Amgen/AstraZeneca
-
CINQAIR/CINQAERO (reslizumab): Teva Pharmaceuticals
Asthma Emerging Drugs
-
Depemokimab (GSK3511294): GlaxoSmithKline
-
Masitinib: AB Science
-
BREZTRI AEROSPHERE (PT010): AstraZeneca/Amgen
Asthma Key Companies
-
GlaxoSmithKline
-
Teva Pharmaceuticals
-
Launch Therapeutics
-
AB Science
-
AstraZeneca
-
Areteia Therapeutics
-
Knopp Biosciences
-
Palobiofarma SL
-
Pivotal S.L.
-
Sterna Biologicals
-
Sanofi
-
Connect Biopharma, and others
For more information, visit Asthma Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Asthma Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Asthma, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Asthma epidemiology in the 7MM
-
Asthma marketed and emerging therapies
-
Asthma companies
-
Asthma market drivers and barriers
Table of Contents:
1 Asthma Market Key Comprehensive Insights
2 Asthma Market Report Introduction
3 Competitive Intelligence Analysis for Asthma
4 Asthma Market Analysis Overview at a Glance
5 Executive Summary of Asthma
6 Asthma Epidemiology and Market Methodology
7 Asthma Epidemiology and Patient Population
8 Asthma Patient Journey
9 Asthma Treatment Algorithm, Asthma Current Treatment, and Medical Practices
10 Key Endpoints in Asthma Clinical Trials
11 Asthma Marketed Therapies
12 Asthma Emerging Therapies
13 Asthma: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Asthma
16 Asthma Market Key Opinion Leaders Reviews
18 Asthma Market Drivers
19 Asthma Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Asthma Epidemiology 2034
DelveInsight’s “Asthma – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Asthma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Asthma Pipeline 2024
“Asthma Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Asthma market. A detailed picture of the Asthma pipeline landscape is provided, which includes the disease overview and Asthma treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/